The Experts below are selected from a list of 6 Experts worldwide ranked by ideXlab platform

L I Huijie - One of the best experts on this subject based on the ideXlab platform.

  • Availability and irreversibility analysis of combustion process for gasoline engine based on two zone model
    Journal of Combustion Science and Technology, 2010
    Co-Authors: L I Huijie
    Abstract:

    To investigate the energy conversion principle in the combustion process of a gasoline engine,a two-zone thermodynamic model was developed.The Change of Availability and loss of irreversibility were taken into account.Cylinder pressure and temperature were calculated as a function of crank angle during the combustion process.Total Availability and Availability destruction terms were calculated as a function of crank angle.The relationship of Availability of unburned zone and burned zone and its relationship with heat release were analyzed.Transfer of charge Availability includes work,Availability transfer of heat transfer and Availability destruction.Charge Availability at the end of combustion is about 47.0% of the total Availability at the start of combustion.Combustion irreversibility is about 18.4% of the total intial Availability,while due to heat transfer,Availability destruction is about 12.3% during the whole combustion process.A shorter combustion duration and a properly postponed combustion are both helpful to reduce Availability destruction.

J. Schüller - One of the best experts on this subject based on the ideXlab platform.

  • Pharmacokinetics of mitoxantrone in patients after 2 h and 24 h intra-arterial administration
    European Journal of Drug Metabolism and Pharmacokinetics, 1990
    Co-Authors: M. J. Czejka, W. Jäger, A. Georgopoulos, J. Schüller
    Abstract:

    The pharmacokinetic parameters of mitoxantrone in patients with liver metastasis after intra-arterial 2 h and 24 h infusion (dosage 12 mg/m^2) were investigated. Peak plasma concentrations were 305±60 ng/ml at 2 h infusion and 244± 89 ng/ml at 24 h infusion. These peak plasma concentrations occurred at 0.9±0.8 h during 2 h infusion and 5.5±3.4 h during 24 h infusion. No significant difference between both intra-arterial administrations in elimination half-life (50–223 h at 2 h infusion, 58–246 h at 24 h infusion) and area under the plasma concentration-time curve (AUC_0−72=11.6 μg/ml.h for 2 h infusion, AUC_0−72=11.2 μg/ml.h for 24 h infusion) could be found. The results indicate that no Change of Availability in the central compartment at infusion of mitoxantrone over a period of 24 h could be achieved. The 2 h infusion lead to sufficient plasma levels with pharmacokinetic parameters of mitoxantrone similar to 24 h infusion and showed a good clinical picture with mild toxicity.

M. J. Czejka - One of the best experts on this subject based on the ideXlab platform.

  • Pharmacokinetics of mitoxantrone in patients after 2 h and 24 h intra-arterial administration
    European Journal of Drug Metabolism and Pharmacokinetics, 1990
    Co-Authors: M. J. Czejka, W. Jäger, A. Georgopoulos, J. Schüller
    Abstract:

    The pharmacokinetic parameters of mitoxantrone in patients with liver metastasis after intra-arterial 2 h and 24 h infusion (dosage 12 mg/m^2) were investigated. Peak plasma concentrations were 305±60 ng/ml at 2 h infusion and 244± 89 ng/ml at 24 h infusion. These peak plasma concentrations occurred at 0.9±0.8 h during 2 h infusion and 5.5±3.4 h during 24 h infusion. No significant difference between both intra-arterial administrations in elimination half-life (50–223 h at 2 h infusion, 58–246 h at 24 h infusion) and area under the plasma concentration-time curve (AUC_0−72=11.6 μg/ml.h for 2 h infusion, AUC_0−72=11.2 μg/ml.h for 24 h infusion) could be found. The results indicate that no Change of Availability in the central compartment at infusion of mitoxantrone over a period of 24 h could be achieved. The 2 h infusion lead to sufficient plasma levels with pharmacokinetic parameters of mitoxantrone similar to 24 h infusion and showed a good clinical picture with mild toxicity.

W. Jäger - One of the best experts on this subject based on the ideXlab platform.

  • Pharmacokinetics of mitoxantrone in patients after 2 h and 24 h intra-arterial administration
    European Journal of Drug Metabolism and Pharmacokinetics, 1990
    Co-Authors: M. J. Czejka, W. Jäger, A. Georgopoulos, J. Schüller
    Abstract:

    The pharmacokinetic parameters of mitoxantrone in patients with liver metastasis after intra-arterial 2 h and 24 h infusion (dosage 12 mg/m^2) were investigated. Peak plasma concentrations were 305±60 ng/ml at 2 h infusion and 244± 89 ng/ml at 24 h infusion. These peak plasma concentrations occurred at 0.9±0.8 h during 2 h infusion and 5.5±3.4 h during 24 h infusion. No significant difference between both intra-arterial administrations in elimination half-life (50–223 h at 2 h infusion, 58–246 h at 24 h infusion) and area under the plasma concentration-time curve (AUC_0−72=11.6 μg/ml.h for 2 h infusion, AUC_0−72=11.2 μg/ml.h for 24 h infusion) could be found. The results indicate that no Change of Availability in the central compartment at infusion of mitoxantrone over a period of 24 h could be achieved. The 2 h infusion lead to sufficient plasma levels with pharmacokinetic parameters of mitoxantrone similar to 24 h infusion and showed a good clinical picture with mild toxicity.

A. Georgopoulos - One of the best experts on this subject based on the ideXlab platform.

  • Pharmacokinetics of mitoxantrone in patients after 2 h and 24 h intra-arterial administration
    European Journal of Drug Metabolism and Pharmacokinetics, 1990
    Co-Authors: M. J. Czejka, W. Jäger, A. Georgopoulos, J. Schüller
    Abstract:

    The pharmacokinetic parameters of mitoxantrone in patients with liver metastasis after intra-arterial 2 h and 24 h infusion (dosage 12 mg/m^2) were investigated. Peak plasma concentrations were 305±60 ng/ml at 2 h infusion and 244± 89 ng/ml at 24 h infusion. These peak plasma concentrations occurred at 0.9±0.8 h during 2 h infusion and 5.5±3.4 h during 24 h infusion. No significant difference between both intra-arterial administrations in elimination half-life (50–223 h at 2 h infusion, 58–246 h at 24 h infusion) and area under the plasma concentration-time curve (AUC_0−72=11.6 μg/ml.h for 2 h infusion, AUC_0−72=11.2 μg/ml.h for 24 h infusion) could be found. The results indicate that no Change of Availability in the central compartment at infusion of mitoxantrone over a period of 24 h could be achieved. The 2 h infusion lead to sufficient plasma levels with pharmacokinetic parameters of mitoxantrone similar to 24 h infusion and showed a good clinical picture with mild toxicity.